NR546 W3 Antipsychotics Table/study guide /latest
version/comprehensive
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP NT)
Potency (if noted. receptor occupancy if noted ) 450 enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: Haldol •Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and decanoate: •Akathisia
vocal utterances in Tourette’s Syndrome Second- approximately 3 •Drug-induced parkinsonism
line treatment of severe behavior problems in weeks Oral: 12-38 •Tardive dyskinesia, dystonia
children of combative, explosive, hyperexcitability hours •Irreversible involuntary dyskinetic movements
Second- line short-term treatment of hyperactive •Galactorrhea, amenorrhea • Dizziness,
children Treatment of schizophrenic patients who Metabolism: sedation
require prolonged parenteral antipsychotic CYP1A2, CYP2D6, •Dry mouth
therapy Bipolar Disorder Behavioral disturbances CYP3A4 •Constipation
in dementias Delirium (with lorazepam) Positive •Urinary retention
symptoms of psychosis, violent or aggressive •Blurred vision
behavior •Decreased sweating
Potency: High potency first-generation •Hypotension
Neurotransmitter(s) affected: •Tachycardia
Blocks dopamine 2 receptors, reducing positive •Hypertension
symptoms of psychosis and combative, explosive, •Weight gain
and hyperactive behaviors Blocks dopamine 2
receptors in the nigrostriatal pathway, improving tics
and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 •Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours •Akathisia
other antipsychotic drugs Positive symptoms of •Priapism
psychosis Motor and autonomic hyperactivity Metabolism: •Drug-induced parkinsonism
Violent or aggressive behavior CYP450 2D6 •Tardive dyskinesia
Potency: Low-potency first-generation •Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 •Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis •Pigmentary retinopathy
•Dizziness, sedation
, NR546 W3 Antipsychotics Table/study guide /latest
version/comprehensive
•Dry mouth
•Constipation
•Blurred vision
•Decreased sweating
•Sexual dysfunction
•Hypotension
•Weight gain
Thiothixene Target symptoms: Schizophrenia, other psychotic Half-Life: 34-35 •Neuroleptic-induced deficit syndrome
disorders, bipolar disorder Reduces positive hours •Akathisia
symptoms in schizophrenia Reduces symptoms of •Drug-induced parkinsonism
acute psychotic mania Reduces negative Metabolism: CYP1A2 •Tardive dyskinesia
symptoms of psychosis Potency: High potency •Irreversible involuntary dyskinetic movements
conventional antipsychotic Neurotransmitter(s) •Galactorrhea, amenorrhea
affected: Blocks dopamine 2 receptors, reducing •Sedation
positive symptoms of psychosis •Dry Mouth
•Constipation
•Vision disturbance
•Urinary retention
•Hypotension
•Tachycardia
•Rare fine lenticular pigmentation
Fluphenazine Target symptoms: Psychotic disorders, bipolar Half-Life: 14-16 •Neuroleptic-induced deficit syndrome
disorder Positive symptoms of psychosis Motor and hours •Akathisia
autonomic hyperactivity Violent or aggressive •Drug-induced parkinsonism
behavior Metabolism: CYP2D6 •Tardive dyskinesia
Potency: High potency conventional antipsychotic •Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 •Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis •Dizziness, sedation
•Dry mouth
•Constipation
•Urinary retention
•Blurred vision
•Decreased sweating
•Depression
version/comprehensive
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative effect metabolism (CYP NT)
Potency (if noted. receptor occupancy if noted ) 450 enzyme)
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target symptoms: Half-Life: Haldol •Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and decanoate: •Akathisia
vocal utterances in Tourette’s Syndrome Second- approximately 3 •Drug-induced parkinsonism
line treatment of severe behavior problems in weeks Oral: 12-38 •Tardive dyskinesia, dystonia
children of combative, explosive, hyperexcitability hours •Irreversible involuntary dyskinetic movements
Second- line short-term treatment of hyperactive •Galactorrhea, amenorrhea • Dizziness,
children Treatment of schizophrenic patients who Metabolism: sedation
require prolonged parenteral antipsychotic CYP1A2, CYP2D6, •Dry mouth
therapy Bipolar Disorder Behavioral disturbances CYP3A4 •Constipation
in dementias Delirium (with lorazepam) Positive •Urinary retention
symptoms of psychosis, violent or aggressive •Blurred vision
behavior •Decreased sweating
Potency: High potency first-generation •Hypotension
Neurotransmitter(s) affected: •Tachycardia
Blocks dopamine 2 receptors, reducing positive •Hypertension
symptoms of psychosis and combative, explosive, •Weight gain
and hyperactive behaviors Blocks dopamine 2
receptors in the nigrostriatal pathway, improving tics
and other symptoms in Tourette’s syndrome
Thioridazine Target symptoms: Used for Schizophrenia in Half-Life: 21-24 •Neuroleptic-induced deficit syndrome
patients who fail to respond to treatment with hours •Akathisia
other antipsychotic drugs Positive symptoms of •Priapism
psychosis Motor and autonomic hyperactivity Metabolism: •Drug-induced parkinsonism
Violent or aggressive behavior CYP450 2D6 •Tardive dyskinesia
Potency: Low-potency first-generation •Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 •Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis •Pigmentary retinopathy
•Dizziness, sedation
, NR546 W3 Antipsychotics Table/study guide /latest
version/comprehensive
•Dry mouth
•Constipation
•Blurred vision
•Decreased sweating
•Sexual dysfunction
•Hypotension
•Weight gain
Thiothixene Target symptoms: Schizophrenia, other psychotic Half-Life: 34-35 •Neuroleptic-induced deficit syndrome
disorders, bipolar disorder Reduces positive hours •Akathisia
symptoms in schizophrenia Reduces symptoms of •Drug-induced parkinsonism
acute psychotic mania Reduces negative Metabolism: CYP1A2 •Tardive dyskinesia
symptoms of psychosis Potency: High potency •Irreversible involuntary dyskinetic movements
conventional antipsychotic Neurotransmitter(s) •Galactorrhea, amenorrhea
affected: Blocks dopamine 2 receptors, reducing •Sedation
positive symptoms of psychosis •Dry Mouth
•Constipation
•Vision disturbance
•Urinary retention
•Hypotension
•Tachycardia
•Rare fine lenticular pigmentation
Fluphenazine Target symptoms: Psychotic disorders, bipolar Half-Life: 14-16 •Neuroleptic-induced deficit syndrome
disorder Positive symptoms of psychosis Motor and hours •Akathisia
autonomic hyperactivity Violent or aggressive •Drug-induced parkinsonism
behavior Metabolism: CYP2D6 •Tardive dyskinesia
Potency: High potency conventional antipsychotic •Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 •Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis •Dizziness, sedation
•Dry mouth
•Constipation
•Urinary retention
•Blurred vision
•Decreased sweating
•Depression
